MAX SENNA MANO
Projetos de Pesquisa
Unidades Organizacionais
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina
37 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 37
conferenceObject Incidence and mortality rates of breast and gynecologic cancers and human development index in the pan-American region(2014) MARTINEZ-MESA, Jeovany; WERUTSKY, Gustavo; MICHIELS, Stefan; SAMPAIO-FILHO, Carlos Alberto; DUENAS, Alfonso; ZARBA, Juan Jose; MANO, Max S.; VILLARREAL-GARZA, Cynthia Mayte; GOMEZ, Henry Leonidas; BARRIOS, Carlos H.- Patterns of post-operative radiotherapy in breast cancer patients after neoadjuvant chemotherapy(2017) LOPES, K. M.; FREITAS, T. B. De; CARVALHO, H. A.; PEREIRA, A. A.; SILVA, S. B.; STUART, S. R.; MANO, M. S.; FILASSI, J. R.; MARTA, G. N.
- Metaplastic breast cancer: A single-institution experience.(2016) SILVA, Aumilto Augusto; LINCK, Rudinei Diogo Marques; LIMA, Julianne Maria da Silva; MATUTINO, Adriana Reis Brandao; SILVA, Saulo Brito; VICENTINI, Maria Fernanda; FELIZOLA, Marcelo; GAGLIATO, Debora De Melo; HOFF, Paulo Marcelo; MANO, Max S.
- Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysis(2020) MANO, Max S.; LOIBL, Sibylle; MAMOUNAS, Eleftherios P.; MINCKWITZ, Gunter von; HUANG, Chiun-Sheng; UNTCH, Michael; WOLMARK, Norman; WAPNIR, Irene L.; YANG, Youngsen; CONLIN, Alison K.; KUEMMEL, Sherko; SAGHATCHIAN, Mahasti; DIGIOVANNA, Michael P.; STRUNK, Claudia; ZIMOVJANOVA, Martina; SONG, Chunyan; LIU, Haying; TESAROWSKI, David; BLOTNER, Steven; LAM, Lisa H.; SMITT, Melanie; GEYER JR., Charles E.
conferenceObject THE ENCHANTTM TRIAL: AN OPEN LABEL MULTICENTER PHASE 2 WINDOW OF OPPORTUNITY STUDY EVALUATING GANETESPIB (STA-9090) MONOTHERAPY IN WOMEN WITH PREVIOUSLY UNTREATED METASTATIC HER2 POSITIVE OR TRIPLE NEGATIVE BREAST CANCER (TNBC)(2012) CAMERON, D.; MANO, M. S.; VUKOVIC, V.; TEOFILOVICI, F.; BRADLEY, R.; AWADA, A.Background Hsp90 is a molecular chaperone required for proper folding and activation of many cancer-promoting proteins. Several Hsp90 clients are oncoproteins known to play a key role in the pathobiology of breast cancer, including HER2, p95-HER2, EGFR, ER, PI3K, AKT, and VEGFR. The inactivation of these oncoproteins by Hsp90 inhibition is a promising approach for breast cancer therapy. Ganetespib is an Hsp90 inhibitor which has shown anti-tumor activity in heavily pretreated patients with lung, breast, and other cancers. Ganetespib is well tolerated without severe liver or common ocular toxicities. In a phase 2 trial, 22 breast cancer patients who had received up to 3 prior lines of chemotherapy including trastuzumab were treated with ganetespib monotherapy. In patients with HER2+ disease, the objective response rate (ORR) was 15% (2/13) and the SD rate was 46% (6/13). Only 3 patients presented with TNBC; one of those patients achieved SD with substantial tumor shrinkage on treatment. Methods This is a single arm international open-label Phase 2 study in patients with HER2 amplified, or triple negative breast cancer. Patients must not have received any prior therapy in the metastatic setting. Prior adjuvant therapy is allowed. Primary endpoint: ORR. Main secondary endpoints include disease control rate, and progression free survival. Additionally, fresh biopsies and serum samples are collected from all patients for determination of predictors of response and mechanisms of resistance to treatment. Patients are treated with ganetespib 150 mg/m2 is given twice weekly of a 4-week cycle for up to 12 weeks. A total of 70 patients are planned for accrual. At the time of submission, the study is receiving IRB approvals in several centers.- Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.(2019) SCHNEEWEISS, Andreas; LOIBL, Sibylle; MAMOUNAS, Eleftherios P.; MINCKWITZ, Gunter von; MANO, Max S.; UNTCH, Michael; HUANG, Chiun-Sheng; RASTOGI, Priya; CONTE, Pier Franco; D'HONDT, Veronique; REDONDO, Andres; STAMATOVIC, Ljiljana; BONNEFOI, Herve R.; SALGUERO, Hugo Raul Castro; FISCHER, Hans Holger; WAHL, Tanya A.; SONG, Chunyan; BLOTNER, Steven; TRASK, Peter; GEYER, Charles E.
conferenceObject A randomized, open-label, phase II study of lapatinib/capecitabine, lapatinib/vinorelbine, or lapatinib/gemcitabine in patients with ErbB2-amplified metastatic breast cancer progressing after taxane treatment: Results of an interim analysis (GLICO-0801/EGF111792)(2012) GOMEZ, Henry Leonidas; NECIOSUP, Silvia P.; TOSELLO, Celia; XAVIER, Patricia; NASCIMENTO, Yeni Neron do; FANELLI, Marcelo; ISMAEL, Gustavo; BINES, Jose; SAMPAIO, Carlos; LERZO, Guillermo Luis; CAPO, Adolfo Miguel; MANO, Max S.; FEIN, Luis; WERUTSKY, Gustavo; BARRIOS, Carlos H.Background: Lapatinib-capecitabine is approved for the treatment of ErbB2-amplified metastatic breast cancer (MBC) after failure to anthracyclines, taxanes and trastuzumab. GLICO-0801 evaluates different lapatinib-based chemotherapy combinations as 1st/2nd line treatment for ErbB2 amplified MBC progressing after taxane treatment. We present the results of a planned safety interim analysis. Methods: This is an open-label, randomized, international, phase II trial exploring lapatinib (L) 1250mg qd in combination with capecitabine 2000mg/m2 d 1-14 (Arm A) or vinorelbine 25mg/m2 d 1 and 8 (Arm B) or gemcitabine 1000mg/m2 d 1 and 8 (Arm C). Primary objective is to determine the clinical benefit rate (defined as CR+PR+SD for ≥24 weeks). This trial is registered at www.clinicaltrials.gov number: NCT01050322 Results: The first83 randomized patients (pts) (Arm A=29, B=28 and C=26) were included in this analysis. Of them, 65 (78%) have discontinued therapy with mean number of cycles of 4.7, 6.2 and 7.5 in arms A, B and C respectively. Eighteen (21%) pts are still on treatment. Median age was 52y (29-84); 80 pts (96%) had PS 0-1; 51 (61%) were postmenopausal. Fifty-six pts (67%) had visceral metastasis, 52 (63%) were treated as 2nd line therapy and 36 (43%) had received prior trastuzumab. Most reported adverse events (AE) (87%) were grade 1-2. The most common AE (any grade) in arm A: diarrhea 72%, hand-foot syndrome 45%, vomiting 39%, anemia 36%; in arm B: diarrhea 75%, neutropenia 68%, nausea 43%, vomiting 39%; in arm C: diarrhea 72%, neutropenia 60%, anemia 44%, increase in ALT 44%. The most frequent serious AE reported in arm A: diarrhea in 3 pts (10%) and thrombocytopenia in 2 pts (7%); in arm B: febrile neutropenia in 2 pts (7%) and in arm C: sepsis in 1 pt (4%). There was one toxic death related to chemotherapy in arm C. Conclusions: There were no unexpected toxicities so far in this trial with most AEs being mild to moderate and manageable. This interim analysis supports the continuation of the study.conferenceObject Biomarker data from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.(2020) DENKERT, Carsten; LAMBERTINI, Chiara; FASCHING, Peter A.; POGUE-GEILE, Katherine L.; MANO, Max S.; UNTCH, Michael; WOLMARK, Norman; HUANG, Chiung-Sheng; LOIBL, Sibylle; MAMOUNAS, Eleftherios P.; MINCKWITZ, Gunter Von; GEYER, Charles E.; BOULET, Thomas; SONG, Chunyan; PHILLIPS, Gail Lewis; NOWICKA, Malgorzata; HAAS, Sanne de; BASIK, MarkconferenceObject Peripheral neuropathy (PN), thrombocytopenia (TCP) and central nervous system (CNS) recurrence: An update of the phase III KATHERINE trial of post-neoadjuvant trastuzumab emtansine (T-DM1) or trastuzumab (H) in patients (pts) with residual invasive HER2-positive breast cancer (BC)(2019) UNTCH, M.; GEYER JR., C. E.; HUANG, C.; LOIBL, S.; WOLMARK, N.; MANO, M. S.; MINCKWITZ, G. von; BRUFSKY, A.; PIVOT, X.; POLIKOFF, J.; FONTANA, A.; KAUFMAN, B.; ALCEDO, J. C.; BOULET, T.; LIU, H.; SONG, C.; MAMOUNAS, E. P.conferenceObject Chemotheraphy acutely impairs neurovascular and hemodynamic responses in patients with breast cancer(2019) SALES, Allan Kluser; NEGRAO, Marcelo; TESTA, Laura; FERREIRA-SANTOS, Larissa; GROEHS, Raphaela; CARVALHO, Bruna; TOSCHI-DIAS, Edgar; ROCHA, Natalia; LAURINDO, Francisco; DEBBAS, Victor Kluser; RONDON, Maria Kluser; MANO, Max; HAJJAR, Ludhmila; HOFF, Paulo; FILHO, Robero; NEGRAO, Carlos